Nanovis Spine today announced the award of a significant research grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (NIH). The grant will fund advanced research evaluating the potential of Nanovis’ FortiCoreTM implant technology combined with the Company’s developmental nanotube surface technology to accelerate the speed and strength of spinal segment stabilization following spinal fusion procedures.
FortiCore’s deeply porous titanium scaffold is a highly differentiated implant.PEEK Optima® by Invibio is injection molded into the scaffold for exceptional integration, while the PEEK center provides the imaging and mechanical properties preferred by surgeons. Nanovis’ nanotube technology forms durable, nanoscale surface features that have demonstrated the ability to improve bone attachment by generating the body’s natural ability to guide healing and cellular responses.
“Support from the NIH is highly selective and underscores the potential of Nanovis’ technology,” said Matt Hedrick, Chief Executive Officer, Nanovis. “Our research and development team includes some of the first scientists to discover
implant nanotechnology alongside innovative and highly accomplished spine surgeons working to develop and deliver commercially viable implants that evolve patient care.”
Nanovis’ mission is to lead its selected markets with science-enhanced, life improving technology. Nanovis applies its patented and proprietary technologies to its ever-increasing number of implant platforms. With patents extending well
into the next decade these technologies are expected to fuel growth for years to come. Nanovis’ technology platforms provide differentiated, science-driven advantages to Nanovis’ products that appeal to surgeons and hospital networks attempting to maximize outcomes with the best technology for their patients. Nanovis has three advanced implant technology platforms, the FortiCore implant family; a PEEK spinal implant deeply porous titanium scaffold endplates which
has entered the U.S. market, and an advanced nanotechnology platform under development, and an innovative anti-colonization and antimicrobial implant platform also under development.
Nanovis is recruiting for Area Business Director positions. Nanovis also welcomes distributor partners seeking a steady flow of products clearly differentiated by new and advanced technology. Nanovis invites interested individuals to review its website or contact the company directly at 1-877-907-NANO.
For more information about Nanovis, FortiCore, and other Nanovis technologies please visit
www.nanovisinc.com or call Nanovis at